AzTrials
AzTrials

SclerodermaNCT02851875

Duke Scleroderma Clinic Patient Registry

An observational study of Scleroderma and Systemic Sclerosis, run by Duke University at 1 site in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The purpose of the Duke Scleroderma Registry (DSScR) is to obtain information about scleroderma. This information could be used in future research to increase the understanding of disease mechanisms, treatments, and outcomes. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Scleroderma, Systemic Sclerosis
What is being tested?
Registry
How many people
42 participants
Where
1 siteUnited States
Study dates
Apr 2016to 7 May 2018
How long will I take part?
10 Years
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients 18 and older with a history of scleroderma or systemic sclerosis.

Who may be able to join

  • Patients with a history of systemic sclerosis or Scleroderma as identified by the 2013 American College of Rheumatology classification criteria

Who cannot join

  • None

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Duke University

    Durham, North Carolina, 27710

Other trials in United States

About this study

The purpose of the Duke Scleroderma Registry (DSScR) is to obtain information about scleroderma. This information could be used in future research to increase the understanding of disease mechanisms, treatments, and outcomes. This research may also help develop new therapies, novel measures of disease assessment or identify previously unknown manifestations of the diseases. A prospectively followed cohort is an integral component of future translational and clinical research programs. A registry for scleroderma would allow for information to be gleaned about patients in "real-world situations" in an effort to improve the reality, generalizability and applicability of information gathered.

Read the detailed description

The Duke Scleroderma Registry (DSScR) will include 3 types of data collected at each standard of care office visit, generally every 3-6 months. The data will include:

  1. Clinical data obtained by clinicians and entered electronically into a secure database
  2. Laboratory, procedure, and imaging data obtained over the course of clinical care
  3. Photographs of clinically relevant physical findings.

Data that will be stored include historical data on patients' disease and concurrent medical conditions, physical exam findings, laboratory values, imaging and other diagnostic testing results, detailed list of medications and treatments, and quality of life questionnaire data. Historical information will include detailed medical, obstetric, surgical, procedural, social, and family history of disease comparable to information gathered at a typical initial visit. No protected health information will be collected or stored on family members. Data collected will be stored in a secure computer database as well as in a clinic note and will be used for patient care purposes. Protected health information (PHI) that will accompany subject data include name, medical record number, address, phone number, date of birth, dates of diagnoses, dates of procedures, and dates of clinic visits.

The database will be maintained indefinitely; there is no planned endpoint to the collection of the data and maintenance of the database as the investigators are planning a long term prospective evaluation of persons with these diseases.

Subjects will be serially approached/recruited from existing patients in the Duke Rheumatology Adult Clinic. The project will be introduced to each prospective subject by someone involved in their clinical care. A waiver of consent and Health Insurance Portability and Accountability Act (HIPAA) authorization has been filed for the Duke Scleroderma Registry. Persons who have been diagnosed with scleroderma will be identified through monitoring of outpatient clinic lists and the inpatient consult service.

Research records will be archived upon completion of the study. Subject initials and study number will be used to identify subjects in the research material and on research specimens. All electronic data is stored on the shared drive and secured through the following Duke Health Technology Services approved methods: access rights granted and terminated for authorized users only, secure laptops and workstations, individual identifier plus password protection, routine electronic back up, network restrictions.

During the initial screening process, no identifying information (e.g., name, address) will be kept. During the consent process, participants will be informed of data storage and confidentiality safeguards, which are practiced according to HIPAA regulations. Each participant will be assigned a unique identifier (ID) number. All data will be de-identified and coded with this number only.

Being tested
Registry
Medical subject headings
Scleroderma, Diffuse, Scleroderma, Systemic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • RegistryOther

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in disease activity as measured by Rodnan Skin Score

    The Rodnan skin score is a discrete measure of skin thickness that can change through time and in response to medication.

    Measured: Change from baseline at 10 years

  2. Change in disease activity as measured by patient reported Scleroderma Health Associated Questionnaire (SHAQ)

    The SHAQ is a measure of health and disability that produces a discrete value that can change through time and in response to medication.

    Measured: Change from baseline at 10 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Aug 2016 (estimated)
  2. Study startApr 2016
  3. Primary completion7 May 2018
  4. Study completion7 May 2018

Why it stopped: Low enrollment and no plans for analysis

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
42 participants (actual)
Target duration
10 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT02851875
Sponsor's protocol ID
Pro00067280
Status last verified
Sep 2020
First submitted
18 Apr 2016
Last updated
29 Jan 2021
Results posted
No
Data monitoring committee
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Scleroderma and Systemic Sclerosis, run by Duke University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 29 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: Low enrollment and no plans for analysis). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in disease activity as measured by Rodnan Skin Score (time frame: Change from baseline at 10 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jan 2021.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in